Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines

Experts Opinion in BioPharm International

“The development of breakthrough fixed-bed bioreactors bring new opportunities in readily developing and scaling adherent platforms as an alternative to stirred-tanks reactors”.

Our Product Manager Alex Chatel & Sr Bioprocess Architect Jean-Christophe Drugmand explore the traditional path from the laboratory to the clinic and the technologies that provide cost-effective commercial production of gene therapies in BioPharm International article.


About our experts

Alex Chatel Product Manager Univercells Technologies Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines

Alex Chatel is the Product Manager for the single-use scale-X bioreactors carbo (10-30 m²) and nitro (200-600 m²), working on the development of their fixed-bed bioreactors technology and integrated DSP platform. Prior to this, he has held positions as an Enterprise Fellow and in technology transfer at University College London and as a Research Engineer at GlaxoSmithKline in Stevenage, UK. Dr Chatel earned his Ph.D. in Biochemical Engineering from University College London, UK and his MEng in Chemical Engineering from The University of Manchester, UK.

Jean-Christophe Drugmand is Senior Bioprocess Architect at Univercells Technologies focusing on innovation and conceptual design. He has a broad range of bioprocess development and bioreactor engineering expertise, including positions as Lab Manager at Pall Biotech and Director of Manufacturing Operations at Novadip prior to joining the Univercells group in 2017. Jean-Christophe earned his PhD in Cellular Bioengineering from the University of Louvain and is an invited professor on animal cell technologies at the Meurice Institute in Brussels since 2010.

Jean-Christophe Durgmand Sr. Bioprocess Architecht Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines